Nektar Therapeutics (NASDAQ:NKTR) Price Target Raised to $151.00

Nektar Therapeutics (NASDAQ:NKTR) had its price objective lifted by analysts at Citigroup from $123.00 to $151.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s target price would indicate a potential upside of 54.57% from the company’s current price.

A number of other analysts have also recently issued reports on NKTR. HC Wainwright boosted their price objective on Nektar Therapeutics from $165.00 to $185.00 and gave the company a “buy” rating in a research report on Monday. Wall Street Zen upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. TD Cowen began coverage on Nektar Therapeutics in a research report on Tuesday, March 17th. They set a “buy” rating on the stock. Piper Sandler restated an “overweight” rating and set a $105.00 price objective on shares of Nektar Therapeutics in a research report on Monday, January 26th. Finally, BTIG Research upped their price target on Nektar Therapeutics from $151.00 to $178.00 and gave the company a “buy” rating in a research report on Monday. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $140.63.

Nektar Therapeutics Price Performance

Shares of NKTR traded down $2.66 on Tuesday, reaching $97.69. 1,025,432 shares of the stock traded hands, compared to its average volume of 1,085,742. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of -9.61 and a beta of 1.16. Nektar Therapeutics has a 12 month low of $7.99 and a 12 month high of $109.00. The stock’s 50-day moving average price is $73.51 and its 200-day moving average price is $58.59.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.69) by $0.91. The business had revenue of $21.81 million for the quarter, compared to analysts’ expectations of $10.44 million. Nektar Therapeutics had a negative return on equity of 380.32% and a negative net margin of 297.07%. As a group, equities research analysts forecast that Nektar Therapeutics will post -10.02 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Nektar Therapeutics news, CEO Howard W. Robin sold 423 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $73.00, for a total value of $30,879.00. Following the sale, the chief executive officer directly owned 75,489 shares in the company, valued at $5,510,697. This represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 3.71% of the stock is owned by company insiders.

Hedge Funds Weigh In On Nektar Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC boosted its stake in Nektar Therapeutics by 336.9% in the first quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock worth $2,463,000 after purchasing an additional 2,807,595 shares in the last quarter. BVF Inc. IL boosted its stake in Nektar Therapeutics by 22.2% in the fourth quarter. BVF Inc. IL now owns 1,559,595 shares of the biopharmaceutical company’s stock worth $65,940,000 after purchasing an additional 283,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in Nektar Therapeutics by 30.0% in the third quarter. Vanguard Group Inc. now owns 948,647 shares of the biopharmaceutical company’s stock worth $53,978,000 after purchasing an additional 219,155 shares in the last quarter. Farallon Capital Management LLC acquired a new position in Nektar Therapeutics in the third quarter worth $45,008,000. Finally, Two Seas Capital LP acquired a new position in Nektar Therapeutics in the fourth quarter worth $31,506,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

Key Nektar Therapeutics News

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Positive 52?week topline data from the REZOLVE?AA Phase 2b extension showed “deepening of responses” and a favorable safety profile, supporting advancement to late?stage development. This is the primary catalyst for the recent rally. 52?Week Topline Results PR
• Positive Sentiment: Analysts reacted bullishly to the trial readout — several firms raised price targets and issued buy ratings (examples include BTIG and HC Wainwright), signaling higher upside expectations if late?stage studies confirm benefit. Analyst Moves
• Neutral Sentiment: Company held/posted conference call/transcript and investor materials to discuss the 52?week topline results — useful for judging durability, responder details and next?step trial design. Presentation/Transcript
• Negative Sentiment: Nektar announced a proposed underwritten public offering to raise $250M of common stock (and pre?funded warrants for certain investors) — a likely near?term overhang due to dilution and typical selling pressure around equity raises. Public Offering Notice
• Negative Sentiment: Multiple law firms have filed or are soliciting lead plaintiffs in securities class actions alleging violations tied to disclosures covering Feb 26–Dec 15/25; several notices and filing deadlines have been publicized — this escalates litigation risk and could pressure the stock if suits proceed or lead to material settlements/expenses. Class Action Notice

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.